These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2261951)

  • 1. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).
    Hellström E; Robèrt KH; Samuelsson J; Lindemalm C; Grimfors G; Kimby E; Oberg G; Winqvist I; Billström R; Carneskog J
    Eur J Haematol; 1990 Nov; 45(5):255-61. PubMed ID: 2261951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes.
    Hellström E; Robèrt KH; Gahrton G; Mellstedt H; Lindemalm C; Einhorn S; Björkholm M; Grimfors G; Udén AM; Samuelsson J
    Eur J Haematol; 1988 May; 40(5):449-59. PubMed ID: 3378598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
    Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
    Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3.
    De Rosa L; Montuoro A; De Laurenzi A
    Biomed Pharmacother; 1992; 46(5-7):211-7. PubMed ID: 1467449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
    García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
    Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation therapy of myelodysplastic syndromes with retinoic acid.
    Ohno R
    Leuk Lymphoma; 1994 Aug; 14(5-6):401-9. PubMed ID: 7812199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia.
    Hellström-Lindberg E; Robèrt KH; Gahrton G; Lindberg G; Forsblom AM; Kock Y; Ost A
    Br J Haematol; 1992 Aug; 81(4):503-11. PubMed ID: 1390236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
    Jehn U; Göldel N; Vehling-Kaiser U
    Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose ara-C in myelodysplastic syndromes (MDS) and acute leukemia following MDS: proposal for a predictive model.
    Hellström-Lindberg E; Robèrt KH; Gahrton G; Lindberg G; Forsblom AM; Kock Y; Ost A
    Leuk Lymphoma; 1994 Feb; 12(5-6):343-51. PubMed ID: 8180598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
    Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
    Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
    Aul C; Schneider W
    Cancer; 1989 Nov; 64(9):1812-8. PubMed ID: 2790694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
    Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
    Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
    Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytarabine-induced pericarditis].
    Yamada T; Tsurumi H; Hara T; Sawada M; Oyama M; Moriwaki H
    Rinsho Ketsueki; 1998 Nov; 39(11):1115-20. PubMed ID: 9866424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol.
    Besa EC; Abrahm JL; Bartholomew MJ; Hyzinski M; Nowell PC
    Am J Med; 1990 Dec; 89(6):739-47. PubMed ID: 2252043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
    Bolwell BJ; Cassileth PA; Gale RP
    Leukemia; 1987 Aug; 1(8):575-9. PubMed ID: 3312846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.